Trial reportJournal of cardiothoracic surgery2025
Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial.
Trial report in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery.
methodsSixty patients diagnosed with lower extremity deep vein thrombosis (DVT) following thoracoscopic lung cancer surgery were randomly assigned to two groups: the experimental group comprising 30 patients treated with rivaroxaban, and the control group consisting of 30 patients treated with low molecular weight heparin (LMWH). The fundamental clinical characteristics of patients in both groups were documented, encompassing parameters, along with pre- and post-surgical lower limb vascular ultrasound findings. Additionally, variations in drainage volume over the initial three days following the procedure were also noted. Patients were subjected to a three-month follow-up period, during which data from one-month and three-month postoperative examinations were collected.
resultsPatients from both groups exhibited satisfactory wound healing postoperatively. D-dimer levels remained stable, and lower extremity vascular ultrasound evaluations showed no signs of additional thrombus formation. Moreover, there were no reported cases of distant postoperative complications such as pleural effusion, gingival bleeding, or gastrointestinal bleeding. Nonetheless, subcutaneous bruising was observed in six patients from the control group, all localized at the sites of LMWH injections.
conclusionRivaroxaban demonstrates efficacy comparable to LMWH in patients with lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery, while exhibiting a superior safety profile compared to LMWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.